Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities

Author(s):  Zur Eyal

Issue:  Mar/Apr 2013 - Volume 17, Number 2
View All Articles in Issue

Page(s):  113-123

Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 1
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 2
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 3
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 4
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 5
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 6
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 7
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 8
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 9
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 10
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 11

Download in electronic PDF format for $75

Abstract:  Nausea and vomiting in pregnancy can have serious adverse effects on the quality of a woman’s life, affecting her occupational, social, and domestic functioning and her general well-being; therefore, it is very important to treat this condition appropriately and effectively. Evidence-based algorithms support the use of oral pyridoxine alone or combined with doxylamine as first-line treatment. Promethazine or dimenhydrinate, known as a second-line treatment, should be added to the first-line treatment or should be added only to pyridoxine according to different algorithms. In most of the world, there is a lack of approved medicines using this combination approach known as the first-line treatment. Therefore, compounding pharmacists should supply the demand by compounding 10-mg pyridoxine hydrochloride and 10-mg doxylamine succinate slow-release capsules. Since transdermal promethazine does not exist worldwide, and, since this medicine has significant added values compared to the oral/rectal dosage forms, compounding pharmacists should offer physicians transdermal promethazine as a second- line therapy in nausea and vomiting in pregnancy. This review summarizes the nausea and vomiting in pregnancy problems and discusses the compounding opportunities that exist in this common and widespread pathology in order to improve a woman's quality of life.

Related Keywords: Eyal Zur, RPh, MBA, nausea, vomiting, pregnancy, hyperemesis gravidarum, pyridoxine, vitamin B6, doxylamine, antihistamine, dehydration, promethazine, dimenhydrinate, transdermal administration, formulation, slow-release capsules, Diclectin, American College of Obstetrics and Gynecology, algorithm, metoclopramide, trimethobenzimide, ondasetron, methylprednisolone, morning sickness

Related Categories: FORMULATIONS, GASTROENTEROLOGY, NUTRITION AND NUTRICEUTICALS, DOSAGE FORMS/DRUG CARRIERS, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE, NEUROLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities
Zur Eyal
Mar/Apr 2013
Pg. 113-123

Nausea and Vomiting in Hospice Patients
Boomsma Diane
Jul/Aug 2000
Pg. 250-251

ABHR Gel in the Treatment of Nausea and Vomiting in the Hospice Patient
Moon Richard B
Mar/Apr 2006
Pg. 95-98

Promethazine 25 mg/mL in Pluronic Lecithin Organogel for Nausea and Vomiting in a Pediatric Patient: A Case Report
Muller George
May/Jun 2009
Pg. 220-221

Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R
, Newton Gail D
May/Jun 2004
Pg. 181-185

Burning Mouth Syndrome: A Discussion of a Complex Pathology
Zur Eyal
May/Jun 2012
Pg. 196-205

Dimenhydrinate 5-mg/mL Oral Liquid
Allen Loyd V Jr
May/Jun 2003
Pg. 217

Promethazine Hydrochloride 2.5-mg/mL Rectal Solution
Allen Loyd V Jr
May/Jun 2008
Pg. 267

Promethazine Hydrochloride 50-mg/mL Injection
Allen Loyd V Jr
Mar/Apr 2012
Pg. 163

Promethazine Hydrochloride 12.5 mg/0.1 mL in PLO Gel
Allen Loyd V Jr
Nov/Dec 2017
Pg. 495

Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study
Glisson James K
, Wood Rebecca L, Kyle Patrick B, Cleary John D
May/Jun 2005
Pg. 242-246

Chemical Stability of Pyridoxine Hydrochloride 100-mg/mL Injection, Preservative Free
Gupta Vishnu D
Jul/Aug 2006
Pg. 318-319

Pyridoxine Hydrochloride 25 mg/mL in Oral Mix and Oral Mix SF Suspension
Allen Loyd V Jr
Nov/Dec 2021
Pg. 505

Pyridoxine Hydrochloride 50 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
Mar/Apr 2022
Pg. 149

Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
Jul/Aug 2004
Pg. 269-274

Evaluation of the Percutaneous Absorption of Promethazine Hydrochloride, In Vitro, Using the Human Ex Vivo Skin Model
Bassani August S
, Banov Daniel, Lehman Paul A
May/Jun 2008
Pg. 270-273

Basics of Compounding: Providing Pharmacy Services to Bariatric Surgery Patients
McElhiney Linda F
Jan/Feb 2018
Pg. 30-39

Compounding Slow-release Capsules: A Comprehensive Review and an Excel Spreadsheet for Faster Calculation of Excipients
Zur Eyal
Jan/Feb 2013
Pg. 10-22

Meperidine HCl 25-mg/mL and Promethazine HCl 25-mg/mL Injection
Allen Loyd V Jr
Jul/Aug 2003
Pg. 301

Metoclophen Nausea Suppositories
Allen Loyd V Jr
Jan/Feb 1997
Pg. 31

Return to Top